clinical trial · NCT04456387
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
Hemophilia ARecombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionRecombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
brief summary
The primary objectives of the study are to evaluate the efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in the Prevention and Treatment of Bleeding in patients with hemophilia A. The secondary objectives are to evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in the prevention and treatment of bleeding episodes, to investigate the quality of life in patients who used the FRSW107.
started
Oct 15, 2020
primary completion
Sep 30, 2021
completion
Sep 30, 2021
last updated
Dec 13, 2023
official title
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in Adolescent and Adult Patients With Hemophilia A.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol